Similar articles for PMID: 36215645

Year	Number of Results
2015	2
2016	8
2017	4
2018	11
2019	17
2020	20
2021	38
2022	27
2023	3
2024	0

1

¹⁷⁷Lu-Vipivotide Tetraxetan (¹⁷⁷Lu-PSMA-617, Pluvicto) Therapy.

Clements S, Tempesta D, Jacene H. Clements S, et al. J Nucl Med Technol. 2022 Sep;50(3):213-214. doi: 10.2967/jnmt.122.264731. J Nucl Med Technol. 2022. PMID: 36215645 Free article. No abstract available.

2

Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.

Keam SJ. Keam SJ. Mol Diagn Ther. 2022 Jul;26(4):467-475. doi: 10.1007/s40291-022-00594-2. Epub 2022 May 13. Mol Diagn Ther. 2022. PMID: 35553387 Free PMC article. Review.

3

Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.

Shah H, Ravi P, Sonpavde G, Jacene H. Shah H, et al. Expert Rev Anticancer Ther. 2022 Nov;22(11):1163-1175. doi: 10.1080/14737140.2022.2139679. Epub 2022 Nov 3. Expert Rev Anticancer Ther. 2022. PMID: 36305305 Review.

4

Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.

Liu X, Fang GC, Lu H, Shi ZD, Chen ZS, Han CH. Liu X, et al. Drugs Today (Barc). 2023 Jan;59(1):37-49. doi: 10.1358/dot.2023.59.1.3476574. Drugs Today (Barc). 2023. PMID: 36811416 Review.

5

Lutetium lu 177 vipivotide tetraxetan (Pluvicto) for prostate cancer.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 2022 Dec 12;64(1665):e207-e208. Med Lett Drugs Ther. 2022. PMID: 36541942 No abstract available.

6

[Measurement of Airborne Radioactivity in the Inpatient Room after Administering [¹⁷⁷Lu]Lu-PSMA-617 to Humans].

Inaki A, Hirata K, Kambara H, Nomura S, Hattori T, Hosono M. Inaki A, et al. Kaku Igaku. 2022;59(1):51-55. doi: 10.18893/kakuigaku.oa.2201. Kaku Igaku. 2022. PMID: 36104246 Free article. Japanese.

7

Automated radiosynthesis of [⁶⁸ Ga]Ga-PSMA-11 and [¹⁷⁷ Lu]Lu-PSMA-617 on the iPHASE MultiSyn module for clinical applications.

Wichmann CW, Ackermann U, Poniger S, Young K, Nguyen B, Chan G, Sachinidis J, Scott AM. Wichmann CW, et al. J Labelled Comp Radiopharm. 2021 Mar;64(3):140-146. doi: 10.1002/jlcr.3889. Epub 2020 Nov 2. J Labelled Comp Radiopharm. 2021. PMID: 33067810 Free PMC article.

8

Predicting benefit from [¹⁷⁷Lu]Lu-PSMA-617 therapy: what do we need to know?

Sartor O. Sartor O. Lancet Oncol. 2022 Nov;23(11):1344-1345. doi: 10.1016/S1470-2045(22)00616-7. Epub 2022 Oct 16. Lancet Oncol. 2022. PMID: 36261051 No abstract available.

9

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.

Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, Kumar AR, Akhurst T, Pattison DA, Beaulieu A, Mooi J, Tran B, Guo C, Kalff V, Murphy DG, Jackson P, Eu P, Scalzo M, Williams S, Hicks RJ, Hofman MS. Violet J, et al. J Nucl Med. 2020 Jun;61(6):857-865. doi: 10.2967/jnumed.119.236414. Epub 2019 Nov 15. J Nucl Med. 2020. PMID: 31732676 Free PMC article. Clinical Trial.

10

Molecular imaging and biochemical response assessment after a single cycle of [²²⁵Ac]Ac-PSMA-617/[¹⁷⁷Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [¹⁷⁷Lu]Lu-PSMA-617 monotherapy.

Rosar F, Hau F, Bartholomä M, Maus S, Stemler T, Linxweiler J, Ezziddin S, Khreish F. Rosar F, et al. Theranostics. 2021 Feb 16;11(9):4050-4060. doi: 10.7150/thno.56211. eCollection 2021. Theranostics. 2021. PMID: 33754047 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

98 results

Results by year